CClinicalTrials.gg
RecruitingNCT06411717Updated May 14, 2024

A Clinical Trial to Evaluate the Efficacy and Safety of Defocusing Lenses in Delaying Myopia Progression

An interventional study of Microstructure lens A and Microstructure lens B in Myopia, sponsored by Suzhou Kerui Medical Technology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 8 Years to 13 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Suzhou Kerui Medical Technology Co., Ltd · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
8 Years to 13 Years
Sex
All
01

Study summary

The objective of this clinical trial was to evaluate the efficacy and safety of defocusing lenses for delaying myopia progression in children and adolescents. A total of 156 subjects meeting the requirements of the study protocol were included. During the study, subjects were required to wear the test product (defocus lens A or defocus lens B) or the control product (aspheric lens) for 12 months, and regular follow-up was required during the wearing process, including various ophthalmological examinations and subjective feelings about wearing the lens. During the study period, the product status, ocular conditions, adverse events and serious adverse events were continuously observed to evaluate the safety and effectiveness of the test product in clinical use.

02

Conditions studied

  • Myopia

Browse trials for

03

In context

Myopia

984 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's planned enrollment of 156 is above the median of 80 across 783 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Suzhou Kerui Medical Technology Co., Ltd is the lead sponsor of 6 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Participants must meet all criteria to be enrolled in the study at the screening visit:

  1. Age 8\~13 years old (including boundary values), gender is not limited;
  2. The spherical degree of subjective optometry in both eyes with cycloplegic muscle paralysis was between -1.00D and -6.00D (including the boundary value) (based on the mean value of subjective optometry), and the equivalent spherical difference of both eyes was less than 1.50D;
  3. Optimal corrected visual acuity ≥1.0 in left and right eye after ciliary muscle paralysis;
  4. In both eyes with cycloplegia, the degree of the column lens was ≤1.50 days;
  5. Voluntarily participate in the clinical study, sign the informed consent, and obtain the written consent of the guardian;

Exclusion criteria

Exclusion Criteria:

Subjects who met any of the following criteria at the time of the screening visit were excluded from the study:

  1. Have a history of eye trauma or intraocular surgery;
  2. Abnormal results of slit-lamp examination (see Annex 1 for details);
  3. fundus examination results ≥ grade 2 (see Annex 1 for details);
  4. Intraocular pressure \< 10mmHg or > 21mmHg or intraocular pressure difference ≥5mmHg;
  5. Patients with other eye diseases, such as uveitis and other inflammation, glaucoma, cataract, fundus disease, eye tumors, eye trauma, dominant strabismus, and any eye lesions affecting visual function;
  6. Associated diseases that may affect the eye (such as acute and chronic sinusitis, diabetes, Down syndrome, rheumatoid arthritis, etc.);
  7. suffering from a mental disorder or other disease that the researcher deems unsuitable for wearing frame glasses;
  8. Use specially designed myopia control lenses such as hard contact lenses (including care products), multifocal contact lenses, progressive multifocal lenses, and atropine drugs within 1 month before screening or during the planned study period;
  9. Participating in other clinical trials within 3 months prior to screening;
  10. Those who cannot perform regular eye examination;
  11. Other investigators consider it inappropriate to participate in this clinical study.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    Trial Group A

    12-month defocusing lens (microstructured lens A)

    Device: Microstructure lens A

  • Experimental
    Trial Group B

    12-month defocusing lens (microstructured lens B)

    Device: Microstructure lens B

  • Active comparator
    Control group

    12 months wearing aspherical lens

    Other: Control group

Interventions

  • DeviceMicrostructure lens A

    Subjects randomized to Trial Group A will be required to wear microstructural lens A (microstructural design type with low defocus ratio) for 12 months

  • DeviceMicrostructure lens B

    Subjects randomized to Trial B will be required to wear microstructural lens B (high defocus ratio microstructural design type) for 12 months

  • OtherControl group

    Subjects randomized to the control group will be required to wear aspherical single-light lenses for 12 months

06

What researchers measure

Primary outcomes

  1. Change value of equivalent spherical lens after cycloplegia (subjective refraction)

    Subjective optometry after ciliary paralysis was measured by blind researchers (who did not participate in the screening and treatment of subjects), and the final equivalent spherical degree was recorded, and the difference between the subjective optometric equivalent spherical results after ciliary paralysis in the baseline period (before wearing lenses) was recorded.

    Time frame: After 12 months of wearing glasses

Secondary outcomes

  1. Equivalent spherical lens strength after ciliary paralysis (subjective optometry)

    The subjects were subjected to subjective refraction after ciliary paralysis by the investigator, and the corresponding value of equivalent spherical mirror was recorded.

    Time frame: Screening period and wearing glasses for 3 months, 6 months, 12 months

  2. Axis length

    The length of the eye axis was measured by the researcher and the corresponding value was recorded.

    Time frame: Screening period and wearing glasses for 3 months, 6 months, 12 months

  3. Regulating sensitivity

    The researchers conducted sensitivity adjustment tests on the subjects and recorded the test results.

    Time frame: Screening period and wearing glasses for 3 months, 6 months, 12 months

  4. Stereopsis

    The researchers tested the subjects' near-stereoscopic vision and recorded the test results.

    Time frame: Screening period and wearing glasses for 3 months, 6 months, 12 months

  5. Corneal curvature

    The subjects were examined for corneal curvature by the investigator and the results were recorded.

    Time frame: Screening period and wearing glasses for 3 months, 6 months, 12 months

  6. Subjective perception rating for wearing a mirror

    According to their subjective feelings, the subjects were evaluated by Visual Analogue Scales (VAS). The VAS score is on a 10cm scale marked with the words "0" and "10" at each end. "0" is comfortable, "10" is unbearable.

    Time frame: On the day of wearing the glasses and 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after wearing the glasses

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Soochow University
    Suzhou, District, Suzhou City, Jiangsu Province, China
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06411717
Lead sponsor
Suzhou Kerui Medical Technology Co., Ltd
Collaborators
Suzhou Mingshi Optical Technology Co., Ltd
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Apr 7, 2024
Primary completion
Nov 7, 2025 (estimated)
Completion
Mar 7, 2026 (estimated)
Last update
May 14, 2024

Study contacts

Jingyan Yao
Contact
yaojingyan@suda.edu.cn
+86 13862578532

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion